BACKGROUND: Infections with Histoplasma can range from asymptomatic to life-threatening acute pulmonary or disseminated disease. Histoplasmosis can be challenging to diagnose and is widely underrecognized. We analyzed insurance claims data to better characterize histoplasmosis testing and treatment practices and its burden on patients. METHODS: We used the IBM MarketScan Research Databases to identify patients with histoplasmosis (International Classification of Diseases, Ninth Revision, Clinical Modification codes 115.00-115.99) during 2012-2014. We analyzed claims in the 3 months before to the 1 year after diagnosis and examined differences between patients with probable (hospitalized or >1 outpatient visit) and suspected (1 outpatient visit) histoplasmosis. RESULTS: Among 1935 patients (943 probable, 992 suspected), 54% had codes for symptoms or findings consistent with histoplasmosis and 35% had ≥2 healthcare visits in the 3 months before diagnosis. Overall, 646 (33%) had any fungal-specific laboratory test: histoplasmosis antibody test (n = 349 [18%]), Histoplasma antigen test (n = 349 [18%]), fungal smear (n = 294 [15%]), or fungal culture (n = 223 [12%]); 464 (24%) had a biopsy. Forty-nine percent of probable patients and 10% of suspected patients were prescribed antifungal medication in the outpatient setting. In total, 19% were hospitalized. Patients' last histoplasmosis-associated healthcare visits occurred a median of 6 months after diagnosis. CONCLUSIONS: Some histoplasmosis patients experienced severe disease, apparent diagnostic delays, and prolonged illness, whereas other patients lacked symptoms and were likely diagnosed incidentally (eg, via biopsy). Low rates of histoplasmosis-specific testing also suggest incidental diagnoses and low provider suspicion, highlighting the need for improved awareness about this disease. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
BACKGROUND:Infections with Histoplasma can range from asymptomatic to life-threatening acute pulmonary or disseminated disease. Histoplasmosis can be challenging to diagnose and is widely underrecognized. We analyzed insurance claims data to better characterize histoplasmosis testing and treatment practices and its burden on patients. METHODS: We used the IBM MarketScan Research Databases to identify patients with histoplasmosis (International Classification of Diseases, Ninth Revision, Clinical Modification codes 115.00-115.99) during 2012-2014. We analyzed claims in the 3 months before to the 1 year after diagnosis and examined differences between patients with probable (hospitalized or >1 outpatient visit) and suspected (1 outpatient visit) histoplasmosis. RESULTS: Among 1935 patients (943 probable, 992 suspected), 54% had codes for symptoms or findings consistent with histoplasmosis and 35% had ≥2 healthcare visits in the 3 months before diagnosis. Overall, 646 (33%) had any fungal-specific laboratory test: histoplasmosis antibody test (n = 349 [18%]), Histoplasma antigen test (n = 349 [18%]), fungal smear (n = 294 [15%]), or fungal culture (n = 223 [12%]); 464 (24%) had a biopsy. Forty-nine percent of probable patients and 10% of suspected patients were prescribed antifungal medication in the outpatient setting. In total, 19% were hospitalized. Patients' last histoplasmosis-associated healthcare visits occurred a median of 6 months after diagnosis. CONCLUSIONS: Some histoplasmosispatients experienced severe disease, apparent diagnostic delays, and prolonged illness, whereas other patients lacked symptoms and were likely diagnosed incidentally (eg, via biopsy). Low rates of histoplasmosis-specific testing also suggest incidental diagnoses and low provider suspicion, highlighting the need for improved awareness about this disease. Published by Oxford University Press for the Infectious Diseases Society of America 2019.
Authors: Paschalis Vergidis; Robin K Avery; L Joseph Wheat; Jennifer L Dotson; Maha A Assi; Smyrna A Antoun; Kassem A Hamoud; Steven D Burdette; Alison G Freifeld; David S McKinsey; Mary E Money; Thein Myint; David R Andes; Cynthia A Hoey; Daniel A Kaul; Jana K Dickter; David E Liebers; Rachel A Miller; William E Muth; Vidhya Prakash; Frederick T Steiner; Randall C Walker; Chadi A Hage Journal: Clin Infect Dis Date: 2015-04-13 Impact factor: 9.079
Authors: Chadi A Hage; Julie A Ribes; Nancy L Wengenack; Larry M Baddour; Maha Assi; David S McKinsey; Kassem Hammoud; Daisy Alapat; N Esther Babady; Michelle Parker; DeAnna Fuller; Aliya Noor; Thomas E Davis; Mark Rodgers; Patricia A Connolly; Boutros El Haddad; L Joseph Wheat Journal: Clin Infect Dis Date: 2011-08-02 Impact factor: 9.079
Authors: C A Kauffman; A G Freifeld; D R Andes; J W Baddley; L Herwaldt; R C Walker; B D Alexander; E J Anaissie; K Benedict; J I Ito; K M Knapp; G M Lyon; K A Marr; V A Morrison; B J Park; T F Patterson; M G Schuster; T M Chiller; P G Pappas Journal: Transpl Infect Dis Date: 2014-03-04 Impact factor: 2.228
Authors: Jonathan D Alpern; Nathan C Bahr; Gabriela Vazquez-Benitez; David R Boulware; Jonathan S Sellman; George A Sarosi Journal: Open Forum Infect Dis Date: 2016-04-19 Impact factor: 3.835
Authors: Joseph Wheat; Thein Myint; Ying Guo; Phebe Kemmer; Chadi Hage; Colin Terry; Marwan M Azar; James Riddell; Peter Ender; Sharon Chen; Kareem Shehab; Kerry Cleveland; Eden Esguerra; James Johnson; Patty Wright; Vanja Douglas; Pascalis Vergidis; Winnie Ooi; John Baddley; David Bamberger; Raed Khairy; Holenarasipur R Vikram; Elizabeth Jenny-Avital; Geetha Sivasubramanian; Karen Bowlware; Barbara Pahud; Juan Sarria; Townson Tsai; Maha Assi; Satish Mocherla; Vidhya Prakash; David Allen; Catherine Passaretti; Shirish Huprikar; Albert Anderson Journal: Medicine (Baltimore) Date: 2018-03 Impact factor: 1.889
Authors: Tafireyi Marukutira; Shirish Huprikar; Nkechi Azie; Shun-Ping Quan; Herwig-Ulf Meier-Kriesche; David L Horn Journal: HIV AIDS (Auckl) Date: 2014-03-13
Authors: Sara Y Tartof; Kaitlin Benedict; Fagen Xie; Gunter K Rieg; Kalvin C Yu; Richard Contreras; Jonathan Truong; Kimberlee Fong; Hung Fu Tseng; Steven J Jacobsen; Rajal K Mody Journal: Emerg Infect Dis Date: 2018-04 Impact factor: 6.883
Authors: Kaitlin Benedict; Stephanie McCracken; Kimberly Signs; Malia Ireland; Victoria Amburgey; Jose Antonio Serrano; Natalie Christophe; Suzanne Gibbons-Burgener; Sara Hallyburton; Kimberly A Warren; Alison Keyser Metobo; Racheal Odom; Matthew R Groenewold; Brendan R Jackson Journal: Open Forum Infect Dis Date: 2020-08-17 Impact factor: 3.835
Authors: Nida Ashraf; Ryan C Kubat; Victoria Poplin; Antoine A Adenis; David W Denning; Laura Wright; Orion McCotter; Ilan S Schwartz; Brendan R Jackson; Tom Chiller; Nathan C Bahr Journal: Mycopathologia Date: 2020-02-10 Impact factor: 2.574